- Lobbying
- Lobbying by Endo Pharmaceuticals
Lobbying Relationship
Bills mentioned
S.525: Pharmaceutical Market Access and Drug Safety Act of 2009
Sponsor: Byron L. Dorgan (D-N.D.)
H.R.1298: Pharmaceutical Market Access and Drug Safety Act of 2009
Sponsor: Marion Berry (D-Ark.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Joseph H. Gibson | Counsel 1995-97, Chief Antitrust Counsel 1997-2001, H Jud Cm Counsel for Legis and Intergov. Affairs, Antitrust Div., DOJ 2001-2002; Chief Legis. Counsel and Parliamentarian, H Jud. Cmte, 2003-2005; Chief of Staff, Rep. L. Smith 2005-2007; Chief Min. Counsel, H Jud Cmte, 2007-2008 |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate